Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tomoko, Yanaihara"'
Autor:
Akira Takakura, Hisashi Mitsufuji, Mayuko Wada, Masaru Kubota, Sakiko Otani, Sachiyo Maki, Ken Katono, Maiko Asakuma, Jiichiro Sasaki, Tomoko Yanaihara, Tomoya Fukui, Shinichiro Ryuge, Masanori Yokoba, Michiko Yamamoto, Satoshi Igawa, Noriyuki Masuda, Masato Katagiri
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1529-1536
We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c228f213890ddca26d20377e9d6681
https://doi.org/10.1007/s00280-012-1858-2
https://doi.org/10.1007/s00280-012-1858-2
Autor:
Shinichiro Ryuge, Sakiko Otani, Nobuatsu Hayashi, Masanori Yokoba, Satoshi Igawa, Tomoko Yanaihara, Michiko Yamamoto, Noriyuki Masuda, Akira Takakura, Y. Nagashima, Mayuko Wada, Masato Katagiri, Sachiyo Maki, Ken Katono, Hisashi Mitsufuji, Masaru Kubota
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1005-1011
In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2006fae15b25e8e4d5eb8fb1450f4380
https://doi.org/10.1007/s00280-011-1795-5
https://doi.org/10.1007/s00280-011-1795-5
Autor:
Hirosuke Kobayashi, Hisashi Mitsufuji, Susumu Arai, Noriyuki Masuda, Masaru Kubota, Shinichiro Ryuge, Sayaka Onoda, Masanori Yokoba, Michiko Yamamoto, Nobuo Yanase, Tomoko Yanaihara, Tadashi Abe, Masato Katagiri, Mayuko Wada, Shintaro Hagiri
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:419-427
We conducted a Phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor. The aim was to determine the maximum tolerated dose (MTD) of amrubicin combined with a fixed dose of CPT-11 as we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e91c82a60ed4c51ed94e3762c6c9a68
https://doi.org/10.1007/s00280-006-0279-5
https://doi.org/10.1007/s00280-006-0279-5
Autor:
Kaori Ishii, Emi Kato, Shintaro Hagiri, Mayumi Wada, Hisashi Mitsufuji, Tadashi Abe, Michiko Yamamoto, Tomoko Yanaihara, Masato Katagiri, Nobuo Yanase, Noriyuki Masuda, Naohiko Tanaka, Hirosuke Kobayashi, Sayaka Onoda, Nobukazu Takada, Masaru Kuboto, Shinichiro Ryuge, Masanori Yokoba
Publikováno v:
Japanese Journal of Clinical Oncology. 35:478-482
Gefitinib is a synthetic, oral anilinoquinazoline specifically designed to inhibit the epidermal growth factor receptor tyrosine kinase, and is the first targeted drug to demonstrate reproducible activity in non-small cell lung cancer patients who do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bee728255bfefec9c34ac2635a92da5
https://doi.org/10.1093/jjco/hyi122
https://doi.org/10.1093/jjco/hyi122
Autor:
Susumu Arai, Akira Takakura, Hisashi Mitsufuji, Hirosuke Kobayashi, Sayaka Onoda, Masaru Kubota, Ryuji Hataishi, Maiko Iwasaki, Nobuo Yanase, Noriyuki Masuda, Yasuto Nishii, Ken Katono, Mayuko Wada, Tomoko Yanaihara, Sakiko Otani, Masato Katagiri, Michiko Yamamoto, Tomoya Fukui, Shinichiro Ryuge, Masanori Yokoba
Publikováno v:
International journal of clinical oncology. 14(4)
Despite the literature indicating adverse interactions between warfarin and cytotoxic agents, whether such an interaction occurs when warfarin and gefitinib are used concomitantly is unknown. We analyzed the prevalence of the concomitant use of warfa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32499cad3a7d65027f4468b433bef2de
https://pubmed.ncbi.nlm.nih.gov/19705244
https://pubmed.ncbi.nlm.nih.gov/19705244
Autor:
Masanori Yokoba, Paul A. Easton, Tadashi Abe, Masato Katagiri, Yasumasa Okada, Tomoko Yanaihara, Yasuto Nishii, Noriyuki Masuda
Publikováno v:
Respiratory physiologyneurobiology. 161(1)
To clarify the mechanism of action of aminophylline on the hypoxic ventilatory response in humans, we analyzed the effects of aminophylline on respiratory neural output. To evaluate the respiratory neural output, we analyzed the electromyogram (EMG)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94772319b4c5bda1f86e9f0ba80e65c8
https://pubmed.ncbi.nlm.nih.gov/18243069
https://pubmed.ncbi.nlm.nih.gov/18243069
Autor:
Tomoko, Yanaihara, Masanori, Yokoba, Masaru, Kubota, Yasuto, Nishii, Matakichi, Miyamoto, Tadashi, Abe, Noriyuki, Masuda, Masato, Katagiri
Publikováno v:
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 44(11)
A 70-year-old non-obese man with no history of cardiopulmonary disease presented 4 times to the emergency room because of sudden onset of seizure during sleep. Each time he recovered within a few hours without any medication. Nocturnal polysomnograph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55b3cc92c7f39389b01a25b60ca70551
https://pubmed.ncbi.nlm.nih.gov/17144578
https://pubmed.ncbi.nlm.nih.gov/17144578
Autor:
Hisashi Mitsufuji, Noriyuki Masuda, Yasuto Nishii, Sayaka Onoda, Shinichiro Ryuge, Masanori Yokoba, Maiko Iwasaki, Takashi Asahara, Ken Katono, Akira Takakura, Tomoya Fukui, Michiko Yamamoto, Akinobu Kurita, Mayuko Wada, Tomoko Yanaihara
Publikováno v:
Oncology Reports. 20
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its active metabolite, SN-38, which is conjugated by hepatic urid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f715efcd76e1a536ac93dab6f6fd02c
https://doi.org/10.3892/or_00000066
https://doi.org/10.3892/or_00000066
Autor:
N. Yanase, Sayaka Onoda, Noriyuki Masuda, E. Kato, Hisashi Mitsufuji, Shinichiro Ryuge, S. Hagiri, Mayuko Wada, Tomoko Yanaihara, Michiko Yamamoto
Publikováno v:
Journal of Clinical Oncology. 23:2070-2070
2070 Background: CPT-11 (topoisomerase I inhibitor) and AMR (topoisomerase II inhibitor) are active against several solid tumors including NSCLC. Based on the preclinical data, this phase I trial w...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3f73994f226085b1bbff5546bbbf21e
https://doi.org/10.1200/jco.2005.23.16_suppl.2070
https://doi.org/10.1200/jco.2005.23.16_suppl.2070